Market capitalization | $75.09m |
Enterprise Value | $54.04m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.40 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-26.54m |
Free cash flow (TTM) Free cash flow | $-20.67m |
Cash position | $21.88m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
7 Analysts have issued a Oncolytics Biotech Inc. forecast:
7 Analysts have issued a Oncolytics Biotech Inc. forecast:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | -0.32 -0.32 |
7%
7%
|
|
EBITDA | -26 -26 |
29%
29%
|
EBIT (operating result) EBIT | -27 -27 |
29%
29%
|
Net profit | -21 -21 |
14%
14%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Head office | Canada |
CEO | Wayne Pisano |
Employees | 27 |
Founded | 1998 |
Website | www.oncolyticsbiotech.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.